Scientists from Regeneron recently uploaded a study write up in the preprint server medRxiv showcasing significantly positive results associated with the company’s monoclonal antibody cocktail known as REGN-CCOV or the combination of casirivimab and imdevimab. The industry-based study team found in a retrospective analysis of patients with immunodeficiencies given the monoclonal antibody cocktail as part…
